Telix Pharmaceuticals (ASX:TLX) has announced that the United States Food and Drug Administration has approved an expanded indication for its Illuccix® product.
This expansion means that Illuccix is now approved in the US to identify and select patients who are candidates for the only FDA-approved prostate-specific membrane antigen (PSMA)- directed radioligand therapy (Pluvicto®).
Telix Pharma says this will enable doctors to have more information to guide patient management and help optimise treatment outcomes.
It is estimated that 32,000 patients each year in the US may be considered for PSMA-directed radioligand therapy.